Evidence map›Paper›PMID 34182128›Full record

ArticlePharmacological research2021

Heteromerization between α

Verònica Casadó-Anguera, Estefanía Moreno, Marta Sánchez-Soto, Ning Sheng Cai, Jordi Bonaventura, Patricia Homar-Ruano, Marcelo Rubinstein, Antoni Cortés, Enric I Canela, Sergi Ferré and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Attention-deficit/hyperactive disorder updates.Frontiers in molecular neuroscience · 2022
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Verònica Casadó-AngueraDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Estefanía MorenoDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Marta Sánchez-SotoIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, United States.
Ning Sheng CaiIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, United States.
Jordi BonaventuraIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, United States; Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse, Intramural Research Program, Baltimore, United States.
Patricia Homar-RuanoDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Marcelo RubinsteinInstitute of Investigation in Genetic Engineering and Molecular Biology, Buenos Aires, Argentina.
Antoni CortésDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Enric I CanelaDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Sergi FerréIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, United States. Electronic address: sferre@intra.nida.nih.gov.
Vicent CasadóDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain. Electronic address: vcasado@ub.edu.
Institut de Biomedicina de la Universitat de BarcelonaNational Institutes of Health · USInstitute for Research in Biomedicine · ES

Funding

Neurotransmitter Receptor Heteromers in the Striatal Spine ModuleZIADA000493 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI FERRE, SERGI · 2009 to 2025
$35.6M
Intramural NIH HHS ZIA DA000493
6 · The paper itself

Abstract

Polymorphic alleles of the human dopamine D

Indexed as

AnimalsAttention Deficit Disorder with HyperactivityCerebral CortexDopamine AgonistsFemaleHEK293 CellsHumansImpulsive BehaviorLigandsMaleMiceMice, Inbred C57BLMice, TransgenicPolymorphism, GeneticProtein BindingReceptors, Adrenergic, alpha-2ADRA2A protein, humanAdra2a protein, mouseDopamine AgonistsDRD4 protein, humanLigandsReceptors, Adrenergic, alpha-2Receptors, Dopamine D4870 trihydrochloride (PubChem CID: 49759035)A-412997 dihydrochloride (PubChem CID: 90488953)ADHDBRL44408 maleate (PubChem CID: 10382026)Cerebral cortexClonidine hydrochloride (PubChem CID: 20179)Dexmedetomidine hydrochloride (PubChem CID: 6918081)Dopamine D(4) receptorGPCRGuanfacine hydrochloride (PubChem CID: 71401)L-745Pramipexole dihydrochloride (PubChem CID: 119569)Receptor heteromerRopinirole (PubChem CID: 5095)Rotigotine hydrochloride (PubChem CID: 180335)RX821002 hydrochloride (PubChem CID: 11957683)α(2A) adrenoceptor

Identifiers

PMID34182128
PMCPMC9885860
OpenAlexW3174232977

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.